NFKB1 and breast cancer: To address this, we combined the NF‐kB inhibitor with the copper chelator in different breast cancer cells (Figure S8, Supporting Information), and observed that this combined therapy strongly enhanced treatment efficacy compared to individual treatments by decreasing cell growth (Figure5A–C; Figures S9A–C and S10A–D, Supporting Information), colony formation (Figure 5D,E; Figure S9D,E, Supporting Information), and increasing cellular apoptosis (Figure 5F,G; Figures S9F–H and S10E–G, Supporting Information).